Reduction in self-harming behaviour after zuclopenthixol decanoate

    loading  Checking for direct PDF access through Ovid


No psychotropic drug is specifically licensed for the management of emotionally unstable borderline personality disorder. Prescribing ‘off-label’ places additional responsibilities on the prescriber and may increase liability if there are adverse effects. This case report describes a patient with borderline personality disorder who was started on zuclopenthixol decanoate with successful outcome in terms of reducing self-harming behaviour and impulsivity.

Related Topics

    loading  Loading Related Articles